Pharmaceutical company NeuroPhage has nailed $15 million in financing for therapeutic drugs for neurodegenerative disorders including Alzheimer’s disease and Parkinson's, the company announced March 25.

Type two diabetes definitively leads to neuronal injury, but the jury is still out whether it contributes to the buildup of beta-amyloid in the brain associated with Alzheimer’s disease, according to a study published March 20 by the Journal of Nuclear Medicine.

A community-wide evaluation of myocardial perfusion imaging (MPI) use throughout the Kaiser Permanente Northern California health system revealed an unexplainable 51 percent dip in MPI from 2006-2011, according to research published today in the Journal of the American Medical Association.

The Medical Imaging and Technology Alliance (MITA) has brought in Terri Wilson as the organization’s director of PET industry policy.

A major backer of the Alzheimer’s Association is pushing to change the way we categorize Alzheimer’s disease based on a brain study published in Neurology. The research places Alzheimer’s firmly in third place as a leading cause of death in America, instead of its current position of sixth.

The global breast imaging market is expected to rise at a compound annual growth rate of 15.37 percent until 2017 reaching a total worth of $5 billion, announced research firm RnRMarketResearch.com today.

F-18 florbetaben, also known as Neuraceq, received U.S. Food and Drug Administration (FDA) approval today as a diagnostic amyloid agent to help rule out Alzheimer’s disease.

Singapore-based Zecotek Photonics has announced that a new micro-channel avalanche photodiode solid-state photo detector (MAPD) to be used in advanced PET technology has received a notice of allowance from the U.S. Patent Office.